Earlier this month, in a truly historic moment, the RTS,S malaria vaccine became the first to be recommended by the WHO for use among children in sub-Saharan Africa and in other regions with moderate to high malaria transmission rates.
This incredible announcement marks a critical step forward in building our armoury of weapons against a disease that still kills over 400,000 people every year.
British company GSK played a pivotal role in the vaccine’s development, highlighting the role that UK expertise can play in the malaria fight. Through continued government investment in malaria research, we can ensure leading scientists have the support they need to continue to innovate – so we can beat this complex, but preventable and treatable disease.